Clinical Decision-Making for a Patient With eBC: Scenario and Strategies

Author(s):

Kevin Kalinsky, MD, MS,Virginia Kaklamani, MD

Panelists discuss how differences in trial designs, including inclusion criteria, dosing, and end points, influence clinical decision-making in the use of CDK4/6 inhibitors for HR+/HER2– early breast cancer (eBC), with a focus on the NATALEE trial’s analysis of patients with no or low nodal involvement, and how recent expanded approval of ribociclib for high-risk node-positive and node-negative eBC patients guides the identification of ideal candidates based on clinical factors.

EP: 1.Introduction and HR+/HER2– eBC Overview

EP: 2.Approaches to eBC Diagnosis and Risk Stratification

EP: 3.CDK4/6 Inhibitors Treatment Options in the eBC Setting

EP: 4.Clinical Trial Considerations for eBC Treatment Selection

Now Viewing

EP: 5.Clinical Decision-Making for a Patient With eBC: Scenario and Strategies

EP: 6.Managing CDK4/6 Inhibitor Toxicities and Encouraging Adherence

Video content above is prompted by the following:

Please describe notable differences in the trial designs or analyses (eg, inclusion criteria, dosing, end points) with these CDK4/6 inhibitors in eBC.
1. How do these differences impact your clinical decision-making?
2. The latest NATALEE trial analysis (N0 subgroup) examines patients with no or low nodal involvement; can you please describe your experience with this patient population?
With the recent expanded approval of ribociclib for node-positive and node-negative HR+/HER2– eBC patients with a high risk of recurrence, what patient characteristics or clinical factors make someone an ideal candidate for adjuvant ribociclib?